References
- NRC (National Research Council). Science and judgment in risk assessment. Washington, DC; National Academy Press (1994)
- Aardema, M. J. & MacGregor, J. T. Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies. Mutat Res 499: 13-25 (2002) https://doi.org/10.1016/S0027-5107(01)00292-5
- Iannaccone, P. M. Toxicogenomics: "the call of the wild chip". Environ Health Perspect 109:8-11 (2001) https://doi.org/10.2307/3434894
- Kultima, K. et al. Valproic acid teratogenicity: A toxicogenomics approach. Environ Health Perspect 112: 1225-1235 (2004) https://doi.org/10.1289/ehp.7034
- Maggioli, J. et al. Toxicogenomic analysis methods for predivtive toxicology. J of Pharmaco and Toxicol Methods 53:31-37 (2006) https://doi.org/10.1016/j.vascn.2005.05.006
- Hansch, C. et al. The expanding role of quantitative structure-activity relationships (QSAR) in toxicology. Toxicol Lett 79:45-53 (1995) https://doi.org/10.1016/0378-4274(95)03356-P
- Tong, W. et al. Assessment of prediction confidence and domain extrapolation of two structure-activity relationship models for predicting estrogen receptor binding activity. Environ Health Perspect 112:1249-1254 (2004) https://doi.org/10.1289/ehp.7125
- Nie, A. Y. et al. Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol Carcinog 45:914-933 (2006) https://doi.org/10.1002/mc.20205
- Hamadeh, H. K. et al. Gene expression analysis reveals chemical-specific profiles. Toxicol Sci 67:219-231 (2002b) https://doi.org/10.1093/toxsci/67.2.219
- Ulrich, R. & Friend, S. H. Toxicogenomics and drug discovery: will new technologies help us produce better drugs? Nat Rev Drug Discov 1:84-88 (2002) https://doi.org/10.1038/nrd710
- Fielden, M. R. et al. A gene expression signature that predicts the future onset of drug-induced renal tubular toxicity. Toxicol Pathol 33:675-683 (2005) https://doi.org/10.1080/01926230500321213
- Jiang, Y. et al. Diagnosis of drug-induced renal tubular toxicity using global gene expression profiles. J Trans Med 5:47-54 (2007) https://doi.org/10.1186/1479-5876-5-47
- Guerreiro, N. et al. Toxicogenomics in drug development. Toxicol Pathol 31:471-479 (2003) https://doi.org/10.1080/01926230390224656
- Uetrecht, J. Prediction of a new drug's potential to cause idiosyncratic reactions. Curr. Opin. Drug Discov Devel 4:55-59 (2001)
- Yang, Y., Blomme, E. A. G. & Waring, J. F. Toxicogenomics in drug discovery: from preclinical studies to clinical trials. Chem Biol Interact 150:71-85 (2004) https://doi.org/10.1016/j.cbi.2004.09.013
- EPA. Arsenic, inorganic. CASRN 7440-38-2. Integrated Risk Information System (IRIS). Available: http://www.epa.gov/iris/subst/0278.htm(1998b)
- International Agency for Research on Cancer, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Overall evaluations of carcinogenicity: An updating of IARC monographs Vol. 1-42, Supplement 7. Lyon, France: IARC Press. (1987)
- Boelsterli, U. A. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 192:307-322 (2003) https://doi.org/10.1016/S0041-008X(03)00368-5
- Masubuchi, Y., Nakayama, S. & Horie, T. Role of mitochondrial permeability transition in diclofenacinduced hepatocyte injury in rats. Hepatology 35:544-551 (2002) https://doi.org/10.1053/jhep.2002.31871
- Ulrich, R. G. et al. Metabolic, idiosyncratic toxicity of drugs: overview of the hepatic toxicity induced by the anxiolytic, panadiplon. Chem Biol Interact 134: 251-270 (2001) https://doi.org/10.1016/S0009-2797(01)00161-2
- Smith, L. L. Key challenges for toxicologists in the 21st century. Trends Pharmacol Sci 22:281-285 (2001) https://doi.org/10.1016/S0165-6147(00)01714-4
- Fielden, M. R. & Zacharewski, T. R. Challenges and limitations of gene expression profiling in mechanistic and predictive toxicology. Toxicol Sci 60:6-10 (2001) https://doi.org/10.1093/toxsci/60.1.6
- FDA. Guidance for industry Pharmacogenomic data submissions. Washington, DC: Food and Drug Administration. Available: www.fda.gov/cder/guidance/ 6400fnl.pdf (2005)
- Salerno, R. A. & Lesko, L. J. Pharmacogenomic data: FDA voluntary and required submission guidance. Pharmacogenomics 5:503-505 (2004) https://doi.org/10.1517/14622416.5.5.503